Sustained Release of Hydrogen by PdH-Te Nanozyme for Anti-Inflammatory Therapy Against Atherosclerosis

Atherosclerosis is induced by the persistent inflammation of the arterial wall. The regulation of inflammation through active drugs can mitigate atherosclerotic lesions, but the therapeutic outcome is limited due to its insufficient efficacy and stability. Herein, a PdH-Te nanozyme with excellent reactive oxygen species (ROS) scavenging capability is designed for anti-inflammatory therapy, thereby preventing foam cell formation to alleviate atherosclerosis. As expected, the PdH-Te nanozyme shows outstanding multiple antioxidant enzyme activities and sustained hydrogen release properties. Benefiting from decreased ROS levels by enzyme catalysis, PdH-Te nanozyme significantly suppresses the pro-inflammatory cytokines for atherosclerosis treatment. Taken together, the presented results demonstrate that inhibition of inflammation based on PdH-Te nanozyme can effectively treat atherosclerosis, identifying an attractive strategy against cardiovascular diseases. In the treatment of atherosclerosis, inflammation-regulated agents are considerably limited. In this work, a PdH-Te nanozyme with excellent multiple antioxidant enzyme activities is fabricated. This PdH-Te nanozyme can efficiently scavenge ROS and sustainably release H2 to suppress the expression of the pro-inflammatory cytokine, thus achieving the inhibition effect of foam cells for attenuating atherosclerosis.image